Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
India sales grew 23.5% YoY with consolidation of Wockhardt products
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Subscribe To Our Newsletter & Stay Updated
